New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020
October 29, 2020 at 07:00 AM EDT
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented during the American Heart Association’s (AHA) Virtual Scientific Sessions 2020, being held from November 13 - November 17, 2020. These new findings will be featured in eight presentations from a variety of academic collaborators based on research or analyses supported by Amarin.
“The robust data to be presented at the upcoming AHA Virtual Scientific Sessions 2020 provide a broad range of new insights into icosapent ethyl, including clinical outcomes and potential mechanisms of action,” said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. “We continue to broaden our understanding of the efficacy and consistency of VASCEPA in addressing persistent cardiovascular risk across various at-risk patient populations.”
Featured Amarin-supported abstracts to be presented at AHA Virtual Scientific Sessions 2020 include:
Additional information on AHA Virtual Scientific Sessions 2020 can be found here.
About Cardiovascular Risk
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.2 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.3,4,5
REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.6 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.7 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.8 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.
About VASCEPA® (icosapent ethyl) Capsules
Indications and Limitation of Use
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:
Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with
Availability of Other Information About Amarin
Amarin Contact Information
Lee M. Stern